BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26916004)

  • 1. Emerging Roles of Extracellular Hsp90 in Cancer.
    Wong DS; Jay DG
    Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
    Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
    J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.
    Nolan KD; Kaur J; Isaacs JS
    Oncotarget; 2017 Mar; 8(12):19323-19341. PubMed ID: 28038472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 and Immune Modulation in Cancer.
    Graner MW
    Adv Cancer Res; 2016; 129():191-224. PubMed ID: 26916006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.
    Li W; Tsen F; Sahu D; Bhatia A; Chen M; Multhoff G; Woodley DT
    Int Rev Cell Mol Biol; 2013; 303():203-35. PubMed ID: 23445811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.
    Gopal U; Bohonowych JE; Lema-Tome C; Liu A; Garrett-Mayer E; Wang B; Isaacs JS
    PLoS One; 2011 Mar; 6(3):e17649. PubMed ID: 21408136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
    Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H
    Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic target Hsp90 and cancer hallmarks.
    Miyata Y; Nakamoto H; Neckers L
    Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and Analysis of Extracellular Hsp90 (eHsp90).
    Cortes S; Baker-Williams AJ; Mollapour M; Bourboulia D
    Methods Mol Biol; 2018; 1709():321-329. PubMed ID: 29177669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S; Neckers L
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.
    Hance MW; Dole K; Gopal U; Bohonowych JE; Jezierska-Drutel A; Neumann CA; Liu H; Garraway IP; Isaacs JS
    J Biol Chem; 2012 Nov; 287(45):37732-44. PubMed ID: 22989880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
    Siegelin MD
    Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know.
    Jay D; Luo Y; Li W
    Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.